CTOs on the Move

AnaptysBio

www.anaptysbio.com

 
AnaptysBio is a privately-held antibody development company focused on novel programs in immuno-oncology and inflammation. The Company`s first-in-class proprietary pipeline includes ANB020, an anti-IL-33 antibody for the treatment of severe adult asthma and peanut allergy, and ANB019, an anti-IL-36 receptor antibody for the treatment of generalized pustular psoriasis. AnaptysBio`s SHM-XEL platform has pioneered the use of in vitro somatic hypermutation for antibody discovery and optimization, which replicates key features of the human immune system and overcomes limitations of prior antibody technologies. AnaptysBio has previously announced partnerships with several biopharmaceutical companies, including Novartis, Gilead, Celgene, Momenta and TESARO.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.anaptysbio.com
  • 10421 Pacific Center Court Suite 200
    San Diego, CA USA 92121
  • Phone: 858.362.6295

Executives

Name Title Contact Details

Funding

AnaptysBio raised $40M on 07/15/2015

Similar Companies

DNA SOLUTIONS

DNA SOLUTIONS is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Trellis Bioscience

Trellis Bioscience is a leader in identifying rare protective antibodies by screening human blood cells.

Pharmacopeia

Pharmacopeia, Inc. is a Cranbury, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arcus Biosciences

Arcus Biosciences is an exciting young company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. Arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the San Francisco bay area, in the heart of the world`s largest biotechnology research hub.

CENTOGENE

CENTOGENE - transforming genetic data into medical decisions. We are one of the worldwide leaders in the field of early genetic diagnostics for rare hereditary diseases. A data repository of genetic data from over 115 countries gives us a unique access to epidemiological, clinical and genetic information on hereditary disorders, including oncogenetic indications. We focus exclusively on providing the highest quality, patient-centred service, verified by multiple international accreditations (ISO, CAP, CLIA), regular pharmaceutical audits and our outstanding short turn-around times for analysis. We believe our medical expertise is based on cutting-edge technologies including whole exome/genome sequencing, innovative biomarkers and continued R&D. Our mutation database (CentoMD®) is the worlds largest for rare genetic diseases and is pivotal to our high-quality diagnostic reporting and comprehensive medical interpretation. CENTOGENE is a key partner for many high-profile pharmaceutical companies who are active in the orphan drug development.